Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
Expert Rev Anti Infect Ther ; 20(8): 1119-1127, 2022 08.
Article in English | MEDLINE | ID: covidwho-1860694

ABSTRACT

INTRODUCTION: Effective treatments for the ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic are limited. The virus has evolved strategies to evade the immune system or hijack immune responses to facilitate infection and escape immune surveillance. Mechanistically, SARS-CoV-2 takes advantage of TLR4 and cytokine-induced integrins to promote its entrance into the cell. Furthermore, the activation of pattern recognition receptors (PRR)-mediated signaling pathways is compromised by SARS-CoV-2 non-structural proteins (NSPs), accessory protein open reading frames (ORFs), and structural proteins upon infection, contributing to viral infection and replication. Host factors necessary for cellular protein synthesis, metabolism, and viral replication can also be inhibited by the SARS-CoV-2 proteins. Exploring specific mechanisms would optimize the therapy methods and benefit drug research and development. AREAS COVERED: We describe pathways and mechanisms by which SARS-CoV-2 evades immune system; these include the mechanisms that operate during virus entry, signaling pathways involved, and processes at RNA and protein levels. EXPERT OPINION: Increased understanding of how viruses interfere with immune responses would provide more evidence for drug development. Drugs targeting conserved viral proteins to inhibit their replication or host factors to enhance immune responses would minimize the impact of virus mutations and prepare for future coronavirus outbreaks.


Subject(s)
COVID-19 , Immunologic Surveillance , SARS-CoV-2 , COVID-19/immunology , COVID-19/virology , Cytokines , Humans , Pandemics , Virus Replication
2.
Mol Biol Rep ; 49(3): 2465-2474, 2022 Mar.
Article in English | MEDLINE | ID: covidwho-1605165

ABSTRACT

Coronavirus outbreak was declared a pandemic by World Health Organization (WHO) in March 2020. The pandemic has led to a devastating loss of life. It has shown us how infectious diseases can cause human existence at stake, and community health is important. The spike protein is the most immunogenic component of the virus. Most vaccine development strategies have focused on the receptor-binding domain (RBD) in the spike protein because it is the most specific target site that recognizes and interacts with human lung cells. Neutralizing antibodies are generated by the humoral immune system and reduce the viral load by binding to spike protein components. Neutralizing antibodies are the proteins secreted by plasma cells and serve as an important part of the defense mechanism. In the recent Covid-19 infection, neutralizing antibodies can be utilized for both diagnostic such as immune surveillance and therapeutic tools such as plasma therapy. So far, many monoclonal antibodies are in the clinical trial phase, and few of them are already in use. In this review, we have discussed details about neutralizing antibodies and their role in combating Covid-19 disease.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibodies, Neutralizing/therapeutic use , Antibodies, Viral/therapeutic use , COVID-19/therapy , SARS-CoV-2/isolation & purification , Animals , Antibodies, Monoclonal/immunology , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Antigens, Viral/immunology , B-Lymphocytes/immunology , COVID-19/immunology , Clinical Trials as Topic , Enzyme-Linked Immunosorbent Assay , Epitopes/immunology , Forecasting , Germinal Center/immunology , Humans , Immunization, Passive , Immunoglobulin Isotypes/immunology , Immunologic Memory , Immunologic Surveillance , Macaca mulatta , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Spike Glycoprotein, Coronavirus/immunology , COVID-19 Serotherapy
3.
Front Immunol ; 12: 635701, 2021.
Article in English | MEDLINE | ID: covidwho-1399135

ABSTRACT

Serological testing is a powerful tool in epidemiological studies for understanding viral circulation and assessing the effectiveness of virus control measures, as is the case of SARS-CoV-2, the pathogenic agent of COVID-19. Immunoassays can quantitatively reveal the concentration of antiviral antibodies. The assessment of antiviral antibody titers may provide information on virus exposure, and changes in IgG levels are also indicative of a reduction in viral circulation. In this work, we describe a serological study for the evaluation of antiviral IgG and IgM antibodies and their correlation with antiviral activity. The serological assay for IgG detection used two SARS-CoV-2 proteins as antigens, the nucleocapsid N protein and the 3CL protease. Cross-reactivity tests in animals have shown high selectivity for detection of antiviral antibodies, using both the N and 3CL antigens. Using samples of human serum from individuals previously diagnosed by PCR for COVID-19, we observed high sensitivity of the ELISA assay. Serological results with human samples also suggest that the combination of higher titers of antiviral IgG antibodies to different antigen targets may be associated with greater neutralization activity, which can be enhanced in the presence of antiviral IgM antibodies.


Subject(s)
Antibodies, Viral/immunology , COVID-19 Serological Testing/methods , COVID-19/diagnosis , COVID-19/prevention & control , Immunologic Surveillance , SARS-CoV-2/immunology , Animals , Antibodies, Viral/blood , Antigens, Viral/immunology , COVID-19/epidemiology , COVID-19/immunology , COVID-19 Serological Testing/standards , Cross Reactions , Dengue Virus/immunology , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay/standards , Female , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Mice , Mice, Inbred BALB C , Sensitivity and Specificity , Zika Virus/immunology
4.
PLoS One ; 16(9): e0253407, 2021.
Article in English | MEDLINE | ID: covidwho-1398926

ABSTRACT

Surveillance testing for infectious disease is an important tool to combat disease transmission at the population level. During the SARS-CoV-2 pandemic, RT-PCR tests have been considered the gold standard due to their high sensitivity and specificity. However, RT-PCR tests for SARS-CoV-2 have been shown to return positive results when performed to individuals who are past the infectious stage of the disease. Meanwhile, antigen-based tests are often treated as a less accurate substitute for RT-PCR, however, new evidence suggests they may better reflect infectiousness. Consequently, the two test types may each be most optimally deployed in different settings. Here, we present an epidemiological model with surveillance testing and coordinated isolation in two congregate living settings (a nursing home and a university dormitory system) that considers test metrics with respect to viral culture, a proxy for infectiousness. Simulations show that antigen-based surveillance testing coupled with isolation greatly reduces disease burden and carries a lower economic cost than RT-PCR-based strategies. Antigen and RT-PCR tests perform different functions toward the goal of reducing infectious disease burden and should be used accordingly.


Subject(s)
Antigens, Viral/immunology , COVID-19 Serological Testing/methods , COVID-19/diagnosis , SARS-CoV-2/genetics , SARS-CoV-2/immunology , COVID-19/virology , False Negative Reactions , False Positive Reactions , Humans , Immunologic Surveillance/immunology , Nursing Homes , Pandemics/prevention & control , Reverse Transcriptase Polymerase Chain Reaction/methods , Sensitivity and Specificity , Universities
5.
Front Immunol ; 12: 718719, 2021.
Article in English | MEDLINE | ID: covidwho-1376701

ABSTRACT

Burkholderia pseudomallei (B. pseudomallei) causes melioidosis, a potentially fatal disease for which no licensed vaccine is available thus far. The host-pathogen interactions in B. pseudomallei infection largely remain the tip of the iceberg. The pathological manifestations are protean ranging from acute to chronic involving one or more visceral organs leading to septic shock, especially in individuals with underlying conditions similar to COVID-19. Pathogenesis is attributed to the intracellular ability of the bacterium to 'step into' the host cell's cytoplasm from the endocytotic vacuole, where it appears to polymerize actin filaments to spread across cells in the closer vicinity. B. pseudomallei effectively evades the host's surveillance armory to remain latent for prolonged duration also causing relapses despite antimicrobial therapy. Therefore, eradication of intracellular B. pseudomallei is highly dependent on robust cellular immune responses. However, it remains ambiguous why certain individuals in endemic areas experience asymptomatic seroconversion, whereas others succumb to sepsis-associated sequelae. Here, we propose key insights on how the host's surveillance radars get commandeered by B. pseudomallei.


Subject(s)
Burkholderia pseudomallei/immunology , Immunologic Surveillance , Melioidosis/immunology , Animals , Burkholderia pseudomallei/pathogenicity , Host Microbial Interactions , Humans , Virulence
6.
Microbiol Spectr ; 9(1): e0022421, 2021 09 03.
Article in English | MEDLINE | ID: covidwho-1319384

ABSTRACT

SARS-CoV-2 has had a disproportionate impact on nonhospital health care settings, such as long-term-care facilities (LTCFs). The communal nature of these facilities, paired with the high-risk profile of residents, has resulted in thousands of infections and deaths and a high case fatality rate. To detect presymptomatic infections and identify infected workers, we performed weekly surveillance testing of staff at two LTCFs, which revealed a large outbreak at one of the sites. We collected serum from staff members throughout the study and evaluated it for binding and neutralization to measure seroprevalence, seroconversion, and type and functionality of antibodies. At the site with very few incident infections, we detected that over 40% of the staff had preexisting SARS-CoV-2 neutralizing antibodies, suggesting prior exposure. At the outbreak site, we saw rapid seroconversion following infection. Neutralizing antibody levels were stable for many weeks following infection, suggesting a durable, long-lived response. Receptor-binding domain antibodies and neutralizing antibodies were strongly correlated. The site with high seroprevalence among staff had two unique introductions of SARS-CoV-2 into the facility through seronegative infected staff during the period of study, but these did not result in workplace spread or outbreaks. Together, our results suggest that a high seroprevalence rate among staff can contribute to immunity within a workplace and protect against subsequent infection and spread within a facility. IMPORTANCE Long-term care facilities (LTCFs) have been disproportionately impacted by COVID-19 due to their communal nature and high-risk profile of residents. LTCF staff have the ability to introduce SARS-CoV-2 into the facility, where it can spread, causing outbreaks. We tested staff weekly at two LTCFs and collected blood throughout the study to measure SARS-CoV-2 antibodies. One site had a large outbreak and infected individuals rapidly generated antibodies after infection. At the other site, almost half the staff already had antibodies, suggesting prior infection. The majority of these antibodies bind to the receptor-binding domain of the SARS-CoV-2 spike protein and are potently neutralizing and stable for many months. The non-outbreak site had two unique introductions of SARS-CoV-2 into the facility, but these did not result in workplace spread or outbreaks. Our results reveal that high seroprevalence among staff can contribute to immunity and protect against subsequent infection and spread within a facility.


Subject(s)
Antibody Formation , COVID-19/epidemiology , COVID-19/immunology , Disease Outbreaks , Long-Term Care , Antibodies, Neutralizing/immunology , Antibodies, Viral/blood , Antibodies, Viral/immunology , Asymptomatic Infections/epidemiology , Binding Sites, Antibody , COVID-19 Testing , Humans , Immunologic Surveillance , RNA, Viral , SARS-CoV-2/genetics , SARS-CoV-2/immunology , Sensitivity and Specificity , Seroepidemiologic Studies , Spike Glycoprotein, Coronavirus/immunology
7.
Cells ; 10(5)2021 05 04.
Article in English | MEDLINE | ID: covidwho-1223956

ABSTRACT

Macrophages comprise a phenotypically and functionally diverse group of hematopoietic cells. Versatile macrophage subsets engage to ensure maintenance of tissue integrity. To perform tissue stress surveillance, macrophages express many different stress-sensing receptors, including purinergic P2X and P2Y receptors that respond to extracellular nucleotides and their sugar derivatives. Activation of G protein-coupled P2Y receptors can be both pro- and anti-inflammatory. Current examples include the observation that P2Y14 receptor promotes STAT1-mediated inflammation in pro-inflammatory M1 macrophages as well as the demonstration that P2Y11 receptor suppresses the secretion of tumor necrosis factor (TNF)-α and concomitantly promotes the release of soluble TNF receptors from anti-inflammatory M2 macrophages. Here, we review macrophage regulation by P2Y purinergic receptors, both in physiological and disease-associated inflammation. Therapeutic targeting of anti-inflammatory P2Y receptor signaling is desirable to attenuate excessive inflammation in infectious diseases such as COVID-19. Conversely, anti-inflammatory P2Y receptor signaling must be suppressed during cancer therapy to preserve its efficacy.


Subject(s)
Inflammation/immunology , Macrophages/immunology , Receptors, Purinergic P2Y/metabolism , Stress, Physiological/immunology , Animals , COVID-19/blood , COVID-19/immunology , Humans , Immunologic Surveillance/drug effects , Immunologic Surveillance/immunology , Inflammation/blood , Inflammation/drug therapy , Macrophages/metabolism , Mice , Neoplasms/blood , Neoplasms/drug therapy , Neoplasms/immunology , Purinergic P2Y Receptor Agonists/pharmacology , Purinergic P2Y Receptor Agonists/therapeutic use , Purinergic P2Y Receptor Antagonists/pharmacology , Purinergic P2Y Receptor Antagonists/therapeutic use , Receptors, Tumor Necrosis Factor/metabolism , STAT1 Transcription Factor/metabolism , Signal Transduction/drug effects , Signal Transduction/immunology , Tumor Necrosis Factor-alpha/metabolism , COVID-19 Drug Treatment
8.
Infect Genet Evol ; 88: 104701, 2021 03.
Article in English | MEDLINE | ID: covidwho-1065475

ABSTRACT

Given the pertinence and acceleration of the spread of COVID-19, there is an increased need for the replicability of data models to verify the veracity of models and visualize important data. Most of these visualizations lack reproducibility, credibility, or accuracy, and are static, which makes it difficult to analyze the spread over time. Furthermore, most current visualizations depicting the spread of COVID-19 are at a global or country level, meaning there is a dearth of regional analysis within a country. Keeping these issues in mind, a replicable, efficient, and simple method to generate regional COVID-19 visualizations mapped with time was created by using the KNIME software, an open-source data analytics platform that can create user-friendly applications or workflows. For this analysis, Albania, Sweden, Ukraine, Denmark, Russia, India, and Australia were closely observed. Among the maps generated for the aforementioned countries, it was noticed that regions with a high population or high population density were often the epicenters within their respective country. The regions caused the virus to spread to their neighboring regions: kickstarting the "domino effect", leading to the infection of another region until the country is overwhelmed with cases-what we call a proximity trend. These dynamic maps are crucial to fighting the pandemic because they can provide insight as to how COVID-19 spreads by providing researchers or officials with an accurate and insightful tool to aid their analysis. By being able to visualize the spread, health and government officials can dive deeper to identify the sources of transmission and attempt to stop or reverse them accordingly.


Subject(s)
COVID-19/epidemiology , COVID-19/transmission , Models, Statistical , Pandemics , SARS-CoV-2/pathogenicity , Software , Australia/epidemiology , COVID-19/diagnosis , COVID-19/virology , Europe/epidemiology , Humans , Immunologic Surveillance , India/epidemiology , Population Density , Workflow
9.
J Clin Virol ; 134: 104709, 2021 01.
Article in English | MEDLINE | ID: covidwho-957191

ABSTRACT

BACKGROUND: The Influenza-like Illness Surveillance Network (ILINet) can indicate the presence of novel, widespread community pathogens. Comparing week-to-week reported influenza-like illness percentages may identify the time of year a novel pathogen is introduced. However, changes in health-seeking behavior during the COVID-19 pandemic call in to question the reliability of 2019-2020 ILINet data as a comparison to prior years, potentially rendering this system less reliable as a novel pathogen surveillance tool. Corroboration of trends seen in the 2019-2020 ILINet data lends confidence to the validity of those trends. This study compares predicted versus reported influenza and influenza-like illnesses in vaccinated adults as a surrogate measure of novel pathogen surveillance. METHODS: An online survey was used to ask US adults their influenza vaccination status, whether they were diagnosed with influenza after vaccination, and whether they experienced an influenza-like illness other than flu. RESULTS: Prevalence of self-reported flu diagnosis in adults age 18-64 who received the flu vaccine between September 1, 2019 and April 15, 2020 (n = 3,225) was 5.8 %, while self-reported flu or flu-like illness (without a flu diagnosis) was 17.9 %. CONCLUSION: Flu and flu-like illness in this sample of flu-vaccinated U.S. adults is significantly higher than predicted, consistent with substantially higher ILI's in 2019-20 compared to ILI's from 2018-19, suggesting that the ILI values reported during the COVID-19 pandemic may be appropriate for comparison to prior years.


Subject(s)
COVID-19/epidemiology , Influenza, Human/epidemiology , Pandemics , Vaccination/statistics & numerical data , Adolescent , Adult , Female , Health Surveys/statistics & numerical data , Humans , Immunologic Surveillance , Influenza A Virus, H1N1 Subtype/pathogenicity , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Male , Middle Aged , SARS-CoV-2/pathogenicity , Self Report , United States/epidemiology
10.
J Med Virol ; 92(11): 2429-2439, 2020 11.
Article in English | MEDLINE | ID: covidwho-838040

ABSTRACT

We report a review of all the experimental and clinical studies performed in the last 60 years on the antiviral activity of inactivated Corynebacterium parvum (Cutibacterium acnes). This bacterium has been originally investigated and used for its oncolytic properties linked to immunomodulating activity, but the interest to successfully prevent and treat bacterial, fungal, and viral infections and lethality, uprising the innate immunity barriers produced many experimental models and very few clinical studies. The dramatic defenseless situation due to impending CoViD-19 pandemic claims to exhume and highlight this aspecific strategy in preventive and therapeutic settings; as a matter of fact, no new or mutated virus can potentially escape to this strong innate immune surveillance strengthened by adequate C. parvum protocols.


Subject(s)
Immunity, Innate , Immunologic Factors/administration & dosage , Immunologic Surveillance , Propionibacterium acnes/immunology , Virus Diseases/immunology , Virus Diseases/therapy , Animals , COVID-19/prevention & control , Clinical Trials as Topic , Humans , Immunologic Factors/therapeutic use , Virus Diseases/prevention & control
12.
Am J Trop Med Hyg ; 102(6): 1189-1190, 2020 06.
Article in English | MEDLINE | ID: covidwho-596275

ABSTRACT

Public health measures are needed to resolve the novel coronavirus disease (COVID-19) pandemic, although a looming economic fallout merits close attention. Early safe reintroduction of immune individuals into the workforce may be essential to protecting the economic welfare of communities. Reverse transcriptase-polymerase chain reaction testing, our primary diagnostic tool to date, has sensitivity and timing concerns, owing to sampling/handling errors, as well as a complex virus-host interaction. Reverse transcriptase-polymerase chain reaction assays do not establish immune status once the virus has been cleared. Targeted serosurveillance for the determination of individuals' potential for transmissibility, particularly if paired with direct pathogen testing, may aid in "cleared for business" decision-making.


Subject(s)
Antibodies, Viral/blood , Betacoronavirus/pathogenicity , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Pandemics , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , RNA, Viral/genetics , Betacoronavirus/genetics , Betacoronavirus/immunology , COVID-19 , Coronavirus Infections/immunology , Coronavirus Infections/virology , Host-Pathogen Interactions/immunology , Humans , Immunity, Humoral , Immunoassay/standards , Immunologic Surveillance , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , Quarantine/methods , Reverse Transcriptase Polymerase Chain Reaction/methods , Reverse Transcriptase Polymerase Chain Reaction/standards , SARS-CoV-2 , United States/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL